NetworkNewsBreaks – Endonovo Therapeutics Inc. (
Post# of 416
(Total Views: 900)
Posted On: 08/02/2019 4:50:52 PM
NetworkNewsBreaks – Endonovo Therapeutics Inc. (ENDV) Positioning SofPulse as Natural Post-Surgical Alternative to Opioids
Endonovo Therapeutics (OTCQB: ENDV) is a developer of safe, wearable and non-invasive medical devices. The company’s SofPulse(R) device targets inflammatory conditions in both the organs and the peripheral tissues. An article discussing the company reads, “SofPulse was recently rolled out in hospitals, nursing centers and wound care centers throughout the U.S. as an effective, postsurgical opioid alternative. As per an official Endonovo announcement, the company plans to be in the evaluation stage with 600 hospitals within the coming 18 months (http://nnw.fm/U9NaU). In addition, Endonovo will distribute SofPulse therapy devices to Veterans Administration facilities and Department of Defense health-care facilities. . . . ‘The public is demanding change in pain-management strategies, especially when it comes to opioid administration,’ Endonovo CEO Alan Collier said in a news release. ‘Very few alternatives exist at the time being, which allows SofPulse to position itself as a natural and safe alternative.’”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Endonovo Therapeutics (OTCQB: ENDV) is a developer of safe, wearable and non-invasive medical devices. The company’s SofPulse(R) device targets inflammatory conditions in both the organs and the peripheral tissues. An article discussing the company reads, “SofPulse was recently rolled out in hospitals, nursing centers and wound care centers throughout the U.S. as an effective, postsurgical opioid alternative. As per an official Endonovo announcement, the company plans to be in the evaluation stage with 600 hospitals within the coming 18 months (http://nnw.fm/U9NaU). In addition, Endonovo will distribute SofPulse therapy devices to Veterans Administration facilities and Department of Defense health-care facilities. . . . ‘The public is demanding change in pain-management strategies, especially when it comes to opioid administration,’ Endonovo CEO Alan Collier said in a news release. ‘Very few alternatives exist at the time being, which allows SofPulse to position itself as a natural and safe alternative.’”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Endonovo Therapeutics, Inc. (ENDV) Stock Research Links
Scroll down for more posts ▼